Hepatic Encephalopathy News and Research

RSS

Using the Microbiome to Predict the Risk of Cirrhosis-Associated Hospitalization

The microbiome is the collection of microorganisms that colonize the human body. Dr. Jasmohan Bajaj discusses the relationship between the microorganisms in the gut and cirrhosis, and how microbiome analysis can be used to predict the risk of cirrhosis-associated hospitalizations.

7 Apr 2018

Drinking during late adolescence could be first step to liver problems in adulthood

Alcohol is the leading cause of liver cirrhosis and liver-related deaths. Results of a large long-term study in Sweden have confirmed that drinking during late adolescence could be the first step towards liver problems in adulthood and that guidelines for safe alcohol intake in men might have to be revised downwards, reports the Journal of Hepatology.

22 Jan 2018

Study shows how probiotic improves integrity of the GI epithelial cell wall in HIV patients

A newly released study published in the Journal of Immunity, Inflammation and Disease and conducted by the Sapienza University of Rome, Italy, found a multi-strain, high concentration, probiotic formulation that helped reconstitute the physical and immunological integrity of the gastrointestinal lining in HIV-1-positive patients on antiretroviral therapy.

3 May 2017

Analysis reveals improved survivorship for acute liver failure patients

More patients hospitalized with acute liver failure - often the result of acetaminophen overdose - are surviving, including those who receive a liver transplant and those who don't, an analysis led by a UT Southwestern Medical Center researcher showed.

5 Apr 2016

European liver patients’ association launches call to action report for the treatment of heapatic encephalopathy

ELPA today launched a new call to action report ‘Time to DeLiver: Getting a Grip on HE’ at the European Parliament in Brussels. This is the first report from Europe to highlight the significant burden of hepatic encephalopathy on patients, their carers, families and society.

14 Oct 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country.

19 May 2015

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc.

20 Apr 2015

Study reveals new target for research into liver disease

In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year.

20 Apr 2015

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.

23 Nov 2014

D-LIVER project aims to help patients with chronic liver disease

A European ICT for Health project aims to improve the quality of life of patients with chronic liver disease, by developing a remote support system to monitor their condition at home.

6 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Scientists from INRA in collaboration with a Chinese team found that the gut microbiota[1] of individuals with liver cirrhosis differ notably from healthy individuals', showing a high proportion of oral bacteria.

26 Jul 2014

Probiotics effectively prevent hepatic encephalopathy in patients with cirrhosis of the liver

Probiotics are effective in preventing hepatic encephalopathy in patients with cirrhosis of the liver, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Hepatic encephalopathy is a deterioration of brain function that is a serious complication of liver disease.

9 Jun 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Study shows impact of hepatic encephalopathy on liver disease patients

New data presented today at the International Liver Congress show the impact of hepatic encephalopathy on liver disease patients and healthcare systems.

11 Apr 2014

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

A new study from the University of Washington has found that performance on Lumosity games can distinguish between patients with cirrhosis of the liver, pre-cirrhotic patients, and healthy controls. The study used Lumosity games as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis. The study is published in the March issue of the American Journal of Gastroenterology.

6 Mar 2014

Phase 2 trial results show GPB reduces hepatic encephalopathy episodes in patients with cirrhosis

Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to reduce hepatic encephalopathy episodes in patients with cirrhosis, with a safety profile similar to placebo.

27 Feb 2014

Smartphone app can quickly screen for cognitive dysfunction in patients with cirrhosis

A smartphone app can quickly screen for cognitive dysfunction often found in patients with cirrhosis, according to a new Virginia Commonwealth University study. The cognitive dysfunction, known as minimal hepatic encephalopathy (MHE), has been difficult to diagnose.

19 Sep 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013